A new drug has been found to improve the cognitive function of Alzheimer's patients in the early stages of the disease.

Research presented at the 2008 Alzheimer's Association International Conference demonstrated that the drug PBT2 reduces levels of amyloid-beta protein associated with Alzheimer's disease.

In a clinical trial involving 78 people with early stage Alzheimer's, either 50mg or 250mg doses of PBT2 were administered over a 12-week period.

Results revealed that participants treated with 250mg of the drug demonstrated a significant improvement in brain function compared to a placebo group.

The researchers also found that levels of amyloid-beta in the cerebrospinal fluid of those on the 250mg dose of PBT2 were reduced by approximately 13 per cent compared to placebo at the end of the 12 weeks.

Lead author of the study, Dr Craig Ritchie from the Division of Neurosciences and Mental Health at Imperial College London, said: "The results of our trial are very encouraging, although it was a relatively small study, which took place over a short period of time.

"Our findings certainly engender much optimism that this drug may have a significant effect on the underlying pathology of Alzheimer's, with a tangible clinical benefit for patients."

Moving forward, Dr Ritchie has called for more long-term trials on a much larger scale.

Login and visit the Alzheimer's Disease Knowledge Centre

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...